Caplin Point Laboratories Limited specializes in producing, developing, and marketing a wide range of generic pharmaceutical formulations globally, particularly excelling in smaller markets like Latin America.

The company is aggressively expanding its global footprint, evidenced by plans to establish a new factory in Mexico and a liquid oral facility in Guatemala, tapping into lucrative markets and benefitting from local government incentives.

Caplin has strategically acquired regulatory approvals which enabled it to become among the few injectable exporters to the USA, thereby solidifying its position in the highly competitive pharmaceutical sector.

Their operation focuses on a unique asset-light model, allowing them to maintain high liquidity with revenues from diverse geographical markets, offsetting potential risks.

A strong inclination towards inorganic growth is visible, with active evaluation of acquisition opportunities to complement their existing business model, aiming for a sustainable expansion path.